A phase 2 study of SRT501 (resveratrol) with bortezomib for patients with relapsed and or refractory multiple myeloma
Tools
Popat, R., Plesner, T., Davies, F., Cook, G., Cook, M., Elliott, P., Jacobson, E., Gumbleton, T., Oakervee, H., Cavenagh, J.
(2013)
A phase 2 study of SRT501 (resveratrol) with bortezomib for patients with relapsed and or refractory multiple myeloma.
BRITISH JOURNAL OF HAEMATOLOGY, 160 (5).
pp. 714-717.
ISSN 0007-1048
Full text not available from this repository.
Item Type: | Letter |
---|---|
Authors (ICR Faculty only): | Davies, Faith |
All Authors: | Popat, R., Plesner, T., Davies, F., Cook, G., Cook, M., Elliott, P., Jacobson, E., Gumbleton, T., Oakervee, H., Cavenagh, J. |
Additional Information: | ISI Document Delivery No.: 092AW Times Cited: 0 Cited Reference Count: 9 Popat, Rakesh Plesner, Torben Davies, Faith Cook, Gordon Cook, Mark Elliott, Peter Jacobson, Eric Gumbleton, Todd Oakervee, Heather Cavenagh, Jamie Wiley-blackwell Hoboken |
Uncontrolled Keywords: | myeloma clinical trials renal medicine apoptosis proteins |
Research teams: | Closed research groups > Myeloma Targeted Treatment |
Depositing User: | Barry Jenkins |
Date Deposited: | 21 Mar 2013 16:44 |
Last Modified: | 13 Nov 2015 16:27 |
URI: | http://publications.icr.ac.uk/id/eprint/12341 |
Actions (login required)
![]() |
View Item |